A Targeted Screening Program for Latent Tuberculosis Infection Among Hematopoietic Cell Transplant Recipients.

摘要: Background US hematopoietic cell transplantation (HCT) recipients have a low prevalence of latent tuberculosis infection (LTBI), but if latently infected they are at risk for progression to active tuberculosis. At our center, all HCT underwent LTBI testing pretransplant by tuberculin skin (TST) until 2013 when we implemented targeted screening program. Our objective was assess the utility program that incorporated questionnaire target TST and QuantiFERON TB Gold (QFT) testing. Methods We performed retrospective cohort study undergoing first transplant from 2014 2016. Patients with positive, indeterminate, subset negative QFT results electronic medical record (EMR) review factors LTBI. Results Among 1290 eligible recipients, 457 (35%) had least 1 factor on questionnaire; nonwhites were more likely undergo (P < .0001). Overall, 16 (1.2%) positive test. Of those screened QFT, 14 (3%) 52 (11%) indeterminate. EMR review, 123 267 (46%) records; 4 both 2 (2%) alone. Two or reported among majority LTBI-positive patients (15 [94%]). All test (n = 16) evaluated, 11 (69%) recommended receive treatment. Conclusions Incorporating allowed an approximate 65% reduction in compared universal this population.